Page last updated: 2024-11-06

avilamycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Avilamycin is a macrolide antibiotic that inhibits bacterial protein synthesis. It is produced by the bacterium *Streptomyces viridochromogenes*. Avilamycin is effective against a broad range of Gram-positive bacteria, including *Staphylococcus aureus* and *Streptococcus pneumoniae*. It is also effective against some Gram-negative bacteria, such as *Haemophilus influenzae*. Avilamycin is not currently marketed as a human antibiotic. However, it has been used in veterinary medicine to treat bacterial infections in animals. Avilamycin is of interest to researchers because it exhibits a unique mode of action, inhibiting the peptidyl transferase activity of the bacterial ribosome. This difference in mechanism of action may lead to the development of new antibiotics that are effective against drug-resistant bacteria.'

avilamycin: similar to Hygromycin B but lacking amino groups [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71674
MeSH IDM0049299

Synonyms (27)

Synonym
11051-71-1
avilamycinum [inn-latin]
avilamycina [inn-spanish]
surmax
ly 048740
avilamycin
hsdb 7029
ly 048 740
avilamycine [inn-french]
avilamycina
avilamycinum
avilamycin [usan:inn:ban]
avilamycine
unii-720wdx56d3
720wdx56d3 ,
DTXSID40891398 ,
DB11375
polyether antibiotic complex produced by streptomyces viridochromogenes eth 23575
ly-048740
inteprity
dtxcid701030518
avilamycine (inn-french)
avilamicina
avilamycinum (latin)
kavault
avilamycinum (inn-latin)
avilamycina (inn-spanish)

Research Excerpts

Overview

Avilamycin is an antibiotic complex produced by cultures of the organism Streptomyces viridochromogenes. It has shown considerable potential for clinical use, although it is presently used as a growth promoter in animal feed.

ExcerptReferenceRelevance
"Avilamycin is an orthosomycin antibiotic that has shown considerable potential for clinical use, although it is presently used as a growth promoter in animal feed. "( The avilamycin resistance determinants AviRa and AviRb methylate 23S rRNA at the guanosine 2535 base and the uridine 2479 ribose.
Bechthold, A; Douthwaite, S; Jakobsen, L; Kirpekar, F; Treede, I; Vester, B; Weitnauer, G, 2003
)
2.32
"Avilamycin is an antibiotic complex produced by cultures of the organism Streptomyces viridochromogenes, strain NRRL 2860. "( Isolation and structural identification of nine avilamycins.
Babbitt, GE; Barker, BJ; Kline, RM; Mertz, JL; Occolowitz, JL; Peloso, JS; Simson, VL, 1986
)
1.97

Effects

ExcerptReferenceRelevance
"Avilamycin has been widely used as an AGP in poultry, but its impact on the structure and function of the gut microbiome of broiler chickens has not been fully elucidated."( Influence of dietary avilamycin on ileal and cecal microbiota in broiler chickens.
Cha, CJ; Choi, JH; Kil, DY; Kim, DW; Kim, GB; Lee, K, 2018
)
1.52

Treatment

ExcerptReferenceRelevance
"Treatment with avilamycin also resulted in a significant reduction in ileal Cp count on day 21 (Pā€‰<ā€‰0.0001) and NE lesion scores on day 17 (Pā€‰<ā€‰0.006) when compared to nonmedicated, challenged birds."( Efficacy of avilamycin for the prevention of necrotic enteritis caused by a pathogenic strain of Clostridium perfringens in broiler chickens.
Bagg, R; McMillan, E; Paradis, MA; Thompson, M; Vessie, G; Zocche, A, 2016
)
1.15

Dosage Studied

Broiler chicks were orally dosed with a hot-water extract of mycelia from Cordyceps sinensis (CS-HW) to assess possible substitution of Avilamycin as an antibiotic growth promoter. During a total period of treatment of 141 days, divided into starter grower and fattening period, the efficacy of avilamycin in a dosage of 80 mg/kg was found.

ExcerptRelevanceReference
"During a total period of treatment of 141 days, divided into starter grower and fattening period, the efficacy of avilamycin in a dosage of 80 mg/kg (starter grower) and 20 mg/kg (fattening) rsp."( [The nutritive effect of avilamycin in swine breeding and fattening].
Dzapo, V; Reiner, G, 1991
)
0.8
"Broiler chicks were orally dosed with a hot-water extract of mycelia from Cordyceps sinensis (CS-HW) to assess possible substitution of Avilamycin as an antibiotic growth promoter (AGP)."( Hot-water extract from mycelia of Cordyceps sinensis as a substitute for antibiotic growth promoters.
Ahn, TS; Koh, JH; Suh, HJ, 2003
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (78)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (3.85)18.7374
1990's10 (12.82)18.2507
2000's38 (48.72)29.6817
2010's23 (29.49)24.3611
2020's4 (5.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.48 (24.57)
Research Supply Index4.51 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index50.33 (26.88)
Search Engine Supply Index2.06 (0.95)

This Compound (36.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (9.76%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other74 (90.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]